Special Issue

Nanobiomaterials with Antimicrobial and Anticancer Applications: Second Edition

Message from the Guest Editors

Nanobiomaterials are nanoscale biomaterials that can be either natural or synthetic and interact with biological systems to perform a specific function. They can serve as an integral part of devices intended to sense a biological response, deliver a drug in a controlled manner, or direct a specific physiological function, and are materials with typical size features in the lower nanometer size range and characteristic mesoscopic properties such as quantum size effects. These properties make them attractive objects of fundamental research and potential new applications. Nanobiomaterials also include inorganic materials functionalized with ligands, biomaterials, and biomolecules. This Special Issue focuses on nanobiomaterials for antimicrobial and anti-cancer properties The interdisciplinary aspect of this Special Issue makes it open to all aspects of nanomaterial- and biomaterial-related research.

Guest Editors

Dr. Rajni Verma

School of Physics, University of Melbourne, Parkville 3010, Australia

Dr. Saurabh Pathak

Department of Materials Science and Engineering, Seoul National University, Seoul, Republic of Korea

Deadline for manuscript submissions

31 December 2025



an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/226286

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).